DAPK3: A Promising Drug Target for Various Diseases (G1613)

Target Name: DAPK3

NCBI ID: G1613

DAPK3

DAPK3: A Promising Drug Target for Various Diseases

In recent years, there has been growing interest in the search for new drug targets that can effectively treat a wide range of diseases. One such drug target that has gained considerable attention is DAPK3, also known as Death-Associated Protein Kinase 3. DAPK3 is a member of the DAPK protein family and plays a critical role in cell death and survival pathways. This article delves into the significance of DAPK3 as a drug target, its potential implications for various diseases, and the ongoing efforts to develop effective therapeutics that target DAPK3.

The Biology of DAPK3

DAPK3 is a serine/threonine kinase enzyme encoded by the DAPK3 gene. It is primarily expressed in the brain, heart, and skeletal muscle tissues. As a member of the DAPK protein family, DAPK3 shares structural similarities with other DAPK family members, including a conserved kinase domain and a unique calmodulin-regulatory domain. DAPK3 is involved in various signaling pathways that regulate cell death, survival, and autophagy.

Role of DAPK3 in Cancer

One of the key areas of interest regarding DAPK3 is its potential role in cancer. Studies have suggested that DAPK3 expression is often altered in various types of cancers, including colorectal, breast, lung, and ovarian cancer. DAPK3 has been linked to the regulation of apoptosis, a process that leads to programmed cell death, and aberrant apoptosis is a hallmark of cancer. Therefore, targeting DAPK3 could potentially restore apoptosis and inhibit cancer cell growth. Preclinical studies using DAPK3 inhibitors have shown promising results, highlighting the potential of DAPK3 as a therapeutic target in cancer treatment.

DAPK3 and Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of neurons in specific regions of the brain. Mounting evidence suggests that DAPK3 may play a crucial role in the pathophysiology of these diseases. Increased levels of DAPK3 have been observed in the brains of patients with Alzheimer's disease, contributing to the formation of neurofibrillary tangles, a hallmark of the disease. In Parkinson's disease, DAPK3 has been implicated in the promotion of neuronal death and the accumulation of misfolded protein aggregates. Targeting DAPK3 may hold promise as a therapeutic strategy for these devastating neurodegenerative diseases.

Cardiovascular Implications of DAPK3

DAPK3 has also been implicated in cardiovascular diseases, including heart failure and ischemic heart disease. Studies have demonstrated that DAPK3 expression is upregulated in failing hearts and is associated with adverse cardiac remodeling and dysfunction. Inhibition of DAPK3 has shown potential in improving cardiac function and reducing cardiac fibrosis in animal models of heart failure. Furthermore, DAPK3 has been linked to the regulation of smooth muscle cell proliferation and vascular remodeling, making it a potential target for the treatment of vascular diseases, such as atherosclerosis and restenosis.

Development of DAPK3 Inhibitors

In recent years, significant efforts have been made to develop potent and selective DAPK3 inhibitors as potential therapeutics. Several small molecule inhibitors targeting DAPK3 have shown promise in preclinical studies. These inhibitors can effectively block DAPK3 activity, leading to the restoration of apoptosis and inhibition of cancer cell growth. However, further research is needed to optimize the selectivity, pharmacokinetics, and safety profiles of DAPK3 inhibitors to ensure their efficacy and minimize potential side effects.

Conclusion

DAPK3, a member of the DAPK protein family, has emerged as a promising drug target in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its involvement in critical cellular processes, such as apoptosis and autophagy, makes DAPK3 an attractive target for therapeutic intervention. The continued research and development of potent DAPK3 inhibitors hold immense potential for the development of novel therapies, offering hope for patients suffering from these debilitating diseases.

Protein Name: Death Associated Protein Kinase 3

Functions: Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization. Involved in the regulation of smooth muscle contraction. Regulates both type I (caspase-dependent) apoptotic and type II (caspase-independent) autophagic cell deaths signal, depending on the cellular setting. Involved in regulation of starvation-induced autophagy. Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. In smooth muscle, regulates myosin either directly by phosphorylating MYL12B and MYL9 or through inhibition of smooth muscle myosin phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to enhance muscle responsiveness to Ca(2+) and promote a contractile state. Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of actin stress fibers into thick bundles. Involved in actin filament focal adhesion dynamics. The function in both reorganization of actin cytoskeleton and focal adhesion dissolution is modulated by RhoD. Positively regulates canonical Wnt/beta-catenin signaling through interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon interferon-gamma activation which is causing RPL13A release from the ribosome, RPL13A association with the GAIT complex and its subsequent involvement in transcript-selective translation inhibition. Enhances transcription from AR-responsive promoters in a hormone- and kinase-dependent manner. Involved in regulation of cell cycle progression and cell proliferation. May be a tumor suppressor

The "DAPK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAPK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets